Economic implications of entecavir treatment in suppressing viral replication in chronic hepatitis B (CHB) patients in China from a perspective of the Chinese Social Security program

Value in Health

Volumn 11, Issue SUPPL. 1, 2008, Pages

  Yuan, Yong ^a   Iloeje, Uchenna ^a   Li, Hong ^a   Hay, Joel ^b   Yao, Guang B ^c  

^a BRISTOL MYERS SQUIBB   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c FUDAN UNIVERSITY   (China)

Author keywords

CHB; China; Cost effectiveness; Entecavir; HBV DNA; Viral load

Indexed keywords

ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; CHINA; CLINICAL TRIAL; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; LIFE EXPECTANCY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NONHUMAN; PHASE 3 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; VIRUS INHIBITION; VIRUS LOAD; VITAL STATISTICS; WORLD HEALTH ORGANIZATION;

EID: 41749120810     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2008.00362.x     Document Type: Conference Paper

References (67)

1. Custer B, Sullivan S, Hazlet T, et al. Global epidemilogy of hepatitis B virus. J Clin Gastroenterol 2004 38 (Suppl. S158 68.
2. Shaw T, Locarnino S. Entecavir for the treatment of chronic hepatitis B. Expert Rev Anti Infect 2004 2 : 853 71.
3. Guan ZQ, Dong ZH, Wang QH, et al. Cost of chronic hepatitis B infection in China. J Clin Gastroenterol 2004 38 (Suppl. S175 8.
4. Liaw YF, Leung NW, Chang TT, et al. Asia Hepatitis Lamivudine Study Group. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000 119 : 172 80.
5. Song BC, Suh DJ, Lee HC, et al. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000 32 : 803 6.
6. Dienstag JL, Schiff ER, Mitchell M, et al. Extended lamivudine pretreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Hepatology 1999 30 : 1082 7.
7. Atkins M, Hunt CM, Brown N, et al. Clinical significance of YMDD mutant hepatitis B virus in a large cohort of lamivudine-treated hepatitis B patients [Abstract]. Hepatology 1998 28 : 319 A.
8. Colonno RJ, Rose RE, Levine SM, et al. Entecavir Two Year Resistance Update: No Resistance Observed in Nucleoside Naïve Patients and Low Frequency Resistance Emergence in Lamivudine Refractory Patients. 56th Annual Meeting of AASLD. San Francisco, CA. Nov 11-15, 2005. Poster 962.
9. Lai CL. The Natural History and Treatment of CHB; Controversies and Consensus. Leon Schiff State of the Art Lecture - AASLD San Francisco. 11-15, Nov, 2005. Available from: http://209.63.37.57/courses/2005/State-of-the-Art/ Lai/player.html [Accessed January, 2006].
10. Chen CJ, Yan HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B Virus DNA level. JAMA 2006 295 : 65 73.
11. Iloeje UH, Yang HI, Su J, et al. Predicting liver cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006 130 : 678 86.
12. Chen CJ, Yang HI, Su J, et al. Elevated serum level of hepatitis B virus (HBV) DNA is an independent risk factor for Hepatocellular carcinoma: a long term follow-up study in Taiwan. Oral presentation 40th European Society for the Study of Liver Meeting. Paris, April 13-17th 2005. J Hepatol 2005 42 (Suppl. 2 16 7.
13. Yang HI, Iloeje UH, Su J, et al. Progression to decompensate cirrhosis in chronic hepatitis B virus infected persons is strongly associated with baseline viral load. Poster presentation 40th European Society for the Study of Liver Meeting. Paris, April 13-17th 2005 EASL. J Hepatol 2005 42 (Suppl. 2 195.
14. Yuan Y, Iloeje U, Hay J, Saab S. Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients. J Manag Care Pharm 2008 14 : 21 33.
15. Yao G. Entecavir is a potent anti-HBV drug superior to lamivudine: experience from clinical trials in China. J Antimicrob Chemother 2007 60 : 201 5.
16. China Statistical Yearbook. Beijing : China Statistics Press, 2004.
17. The Vital Statistics of China. Beijing : Ministry of Health, 2004.
18. Durand-Zaleski I, Zaleski S. DEALE-ing and discounting: a simple way to compute the accrued costs of preventive strategies. Med Decis Making 1994 14 : 98 103.
19. Bolondi L, Sofia S, Siringo S, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001 48 : 251 9.
20. Fattovich G, Pantalena M, Zagni I, et al. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol 2002 97 : 2886 95.
21. Levy AR, Kowdley KV, Iloeje UH, et al. The impact of chronic hepatitis B disease progression on quality of life: a multinational study of health state preferences from infected and uninfected persons. Value Health 2008 (Online Early Articles).
22. Chien RN, Yeh CT, Tsai SL, et al. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 2003 38 : 1267 73.
23. Kanwal F, Gralnek IM, Martin P, et al. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med 2005 142 : 821 31.
24. Lok AS, McMahon BJ. American association for the study of liver diseases practice guidelines: chronic hepatitis B. American Association for the Study of Liver Diseases website [updated December, 2003]. Available from: [Accessed October 13, 2004].
25. Hay J. Where's the value in health care? Value Health 2006 9 : 1 3.
26. WHO. Macroeconomics and Health: Investing in Health for Economic Development-Report of the Commission on Macroeconomics and Health. Geneva, Switzerland : World Health Organization, 2001.
27. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006 4 : 936 62.
28. Chen G, Lin W, Shen F, et al. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol 2006 101 : 1797 803.
29. Tang B, Kruger WD, Chen G, et al. Hepatitis B viremia is associated with increased risk of hepatocellular carcinoma in chronic carriers. J Med Virol 2004 72 : 35 40.
30. Mahmood S, Niiyama G, Kamei A, et al. Influence of viral load and genotype in the progression of hepatitis B-associated liver cirrhosis to hepatocellular carcinoma. Liver Int 2005 25 : 220 5.
31. Yu MW, Yeh SH, Chen PJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005 16 : 265 72.
32. Ohkubo K, Kato Y, Ichikawa T, et al. Viral load is a significant prognostic factor for hepatitis B virus-associated hepatocellular. Cancer 2002 94 : 2663 8.
33. Ohata K, Hamasaki K, Toriyama K, et al. High viral load is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Clin Gastroenterol Hepatol 2004 19 : 670 5.
34. Mommeja-Marin H, Mondou E, Blum R, et al. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology 2003 37 : 1309 19.
35. Marco VD, Marzano A, Lampertico P, et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004 40 : 883 91.
36. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003 348 : 800 7.
37. Qi X, Snow A, Thibault V, et al. Long-term incidence of adefovir diprivoxil resistance in chronic hepatitis B patients after 144 weeks of therapy [Abstract]. J Hepatol 2004 40 : 57 M, Yurdaydin C, Sollano J, et al. AI463026 BEHoLD Study Group. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006 130 : 2039 49.
38. Lai CL, Shouval D, Lok AS, et al. BeHoLD AI463027 Study Group. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006 354 : 1011 20.
39. Lai CL, Chien RN, Leung NW, et al. Asia Hepatitis Lamivudine Study Group. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998 339 : 61 8.
40. Chan HL, Leung NW, Hui AY, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 2005 142 : 240 50.
41. Tassopoulos NC, Volpes R, Pastore G, et al. Lamivudine Precore Mutant Study Group. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999 29 : 889 96.
42. Kapoor D, Guptan RC, Wakil SM, et al. Beneficial effects of lamivudine in hepatitis B virus-related decompensate cirrhosis. J Hepatol 2000 33 : 308 12.
43. Yao FY, Terrault NA, Freise C, et al. Lamivudine treatment is beneficial in patients with severely decompensate cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 2001 34 : 411 6.
44. Yao FY, Bass NM. Lamivudine treatment in patients with severely decompensate cirrhosis due to replicating hepatitis B infection. J Hepatol 2000 33 : 301 7.
45. Nikolaidis N, Vassiliadis T, Giuleme O, et al. Effect of lamivudine treatment in patients with decompensate cirrhosis due to anti-HBe positive/HBeAg-negative chronic hepatitis B. Clin Transplant 2005 19 : 321 6.
46. Hann HW, Fontana RJ, Wright T, et al. United States Lamivudine Compassionate Use Study Group. A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensate hepatitis B virus-related cirrhosis. Liver Transpl 2003 9 : 49 56.
47. Tseng PL, Lu SN, Tung HD, et al. Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensate liver cirrhosis. J Viral Hepat 2005 12 : 386 92.
48. Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for decompensate cirrhosis resulting from chronic hepatitis B. Hepatology 2000 31 : 207 10.
49. Bae SH, Yoon SK, Choi JY, et al. Timing of lamivudine administration according to Child class in patients with decompensate cirrhosis. J Gastroenterol Hepatol 2005 20 : 1527 32.
50. Sponseller CA, Bacon BR, Di Bisceglie AM. Clinical improvement in patients with decompensate liver disease caused by hepatitis B after treatment with lamivudine. Liver Transpl 2000 6 : 715 20.
51. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006 43 : 209 20.
52. Dai MS, Wu PF, Shyu RY, et al. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration. Liver Int 2004 24 : 540 6.
53. Idilman R, Arat M, Soydan E, et al. Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies. J Viral Hepat 2004 11 : 141 7.
54. Jang JW, Choi JY, Bae SH, et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology 2006 43 : 233 40.
55. Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003 125 : 1742 9.
56. Lee GW, Ryu MH, Lee JL, et al. The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with Non-Hodgkin's lymphoma who receive cytotoxic chemotherapy. J Korean Med Sci 2003 18 : 849 54.
57. Lim LL, Wai CT, Lee YM, et al. Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients. Aliment Pharmacol Ther 2002 16 : 1939 44.
58. Nagamatsu H, Itano S, Nagaoka S, et al. Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy. Am J Gastroenterol 2004 99 : 2369 75.
59. Yeo W, Ho WH, Hui P, et al. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res Treat 2004 88 : 209 15.
60. Yeo W, Chan PK, Ho WM, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004 22 : 927 34.
61. Yeo W, Hui EP, Chan AT, et al. Prevention of hepatitis B virus reactivation in patients with nasopharyngeal carcinoma with lamivudine. Am J Clin Oncol 2005 28 : 379 84.
62. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004 351 : 1521 31.
63. Enriquez AD, Campbell MS, Reddy KR. Cost-effectiveness of suppressing hepatitis B virus DNA in immune tolerant patients to prevent hepatocellular carcinoma and cirrhosis. Aliment Pharmacol Ther 2007 26 : 383 91.
64. Lai CL, Yuen MF. The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points. Ann Intern Med 2007 147 : 58 61.
65. Fung SK, Chae HB, Fontana RJ, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006 44 : 283 90.
66. Marcellin P, Change T-T, Lim S, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003 348 : 808 16.
67. Leung N, Peng C, Sollano J, et al. Entecavir results in greater HBV DNA reduction vs adefovir in chronically infected HBeAg(+) antiviral-naïve adults: 24-week results (E.A.R.L.Y. study). Hepatology 2006 44 (4 Suppl. 1 554A (Abstract 982).